Ann: Core patent granted in Australia , page-29

Unwanted immunogenicity, its characteristics, and clinical significance is at present very difficult, if not impossible to predict based on simple models.

I am simply questioning the blanket statement that all phylomers, being up to 50mer, will have problems - this is not justified. Even some human antibody therapeutics can evoke a significant anti-body response.

Phylomer libraries are not drug libraries. Phylomers are screened for activity; to produce a drug requires further transformation (for stability, activity, anti-toxicity, etc.) - pharmacology properties.

I have a friend with a PhD from Harvard Medical School and UMASS where he worked as an oncologist and immunologist. I'll get his view on phylomer immunogenicity, phage display and yeast-two-hybrid screening technologies for peptides and report back to the thread.